PBE
Invesco Biotechnology & Genome ETF
ETF
$95.07−0.03 (−0.03%)Close Oct 2, 2026
Top holdings
33 in all, as of Jul 31, 2026| Holding | Weight (%) | Value |
|---|---|---|
| Invesco Private Prime Fund | 12.9 | $36.3M |
| REGNRegeneron Pharmaceuticals, Inc. | 5.5 | $15.4M |
| AMGNAmgen Inc. | 5.2 | $14.7M |
| CDNACareDx, Inc. | 5.0 | $14.2M |
| VRTXVertex Pharmaceuticals Inc. | 5.0 | $14.1M |
| Invesco Private Government Fund | 5.0 | $14M |
| RPRXRoyalty Pharma PLC | 4.9 | $13.9M |
| BIIBBiogen Inc. | 4.8 | $13.5M |
| GILDGilead Sciences, Inc. | 4.4 | $12.5M |
| UTHRUnited Therapeutics Corp. | 4.1 | $11.5M |
Asset classes
- Stocks
- 100.0%
- Cash and equivalents
- 17.9%
- Net other assets
- −18.0%
Stock sectors
- Health Care
- 100.0%
Countries
- United States
- 90.6%
- United Kingdom
- 4.9%
- Netherlands
- 2.9%
- Cayman Islands
- 1.6%